Clioquinol

Last updated
Clioquinol
Clioquinol.png
Clioquinol 3D ball.png
Clinical data
Trade names Cortin
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a682367
Routes of
administration
topical only
ATC code
Legal status
Legal status
Identifiers
  • 5-Chloro-7-iodo-quinolin-8-ol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.004.533 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C9H5ClINO
Molar mass 305.50 g·mol−1
3D model (JSmol)
  • Ic1c(O)c2ncccc2c(Cl)c1
  • InChI=1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H Yes check.svgY
  • Key:QCDFBFJGMNKBDO-UHFFFAOYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Clioquinol (iodochlorhydroxyquin) tradename Entero-Vioform is an antifungal drug and antiprotozoal drug. It is neurotoxic in large doses. It is a member of a family of drugs called hydroxyquinolines which inhibit certain enzymes related to DNA replication. The drugs have been found to have activity against both viral and protozoal infections. [1]

Contents

Antiprotozoal use

A 1964 report described the use of clioquinol in both the treatment and prevention of shigella infection and Entamoeba histolytica infection in institutionalized individuals at Sonoma State Hospital in California. The report indicates 4000 individuals were treated over a 4-year period with few side effects. [2]

Several recently reported journal articles describing its use as an antiprotozoal include:

Subacute myelo-optic neuropathy

Clioquinol's use as an antiprotozoal drug has been restricted or discontinued in some countries due to an event in Japan where over 10,000 people developed subacute myelo-optic neuropathy (SMON) between 1957 and 1970. The drug was used widely in many countries before and after the SMON event without similar reports. [6] As yet, no explanation exists as to why it produced this reaction, and some researchers have questioned whether clioquinol was the causative agent in the disease, noting that the drug had been used for 20 years prior to the epidemic without incident, and that the SMON cases began to reduce in number prior to the discontinuation of the drug. [7] Theories suggested have included improper dosing, the permitted use of the drug for extended periods of time, [8] and dosing which did not consider the smaller average stature of Japanese; however a dose dependent relationship between SMON development and clioquinol use was never found, suggesting the interaction of another compound. Researchers have also suggested the SMON epidemic could have been due to a viral infection with an Inoue-Melnick virus. [9]

Topical use

Clioquinol is a constituent of the prescription medicine Vioform, which is a topical antifungal treatment. It is also used in the form of a cream (and in combination with betamethasone or fluocinolone) in the treatment of inflammatory skin disorders.[ citation needed ]

Potential use as a preventive or treatment in prostate cancer

It has long been recognized that normal prostate cells have high zinc content through ZIP1 mediated uptake, and have low respiration (OXPHOS ATP generation is diverted to citrate export for sperm energetics). Prostate cancer cells have downregulated ZIP1 transporters which leads to greater ATP generation which is diverted to cancer proliferation, an example of a normal-like metabolic phenotype instead being malignant. The zinc ionophore clioquinol was shown in mice to restore zinc levels and stop the growth of prostate tumors. [10]

Use in neurodegenerative diseases

Research at UCSF indicates that clioquinol appears to block the genetic action of Huntington's disease in mice and in cell culture. [11]

Recent animal studies have shown that clioquinol can reverse the progression of Alzheimer's, Parkinson's and Huntington's diseases. [12] According to Siegfried Hekimi and colleagues at McGill's Department of Biology, clioquinol acts directly on a protein called Clk-1, often informally called “clock-1,” and might slow down the aging process. They theorize that this may explain the apparent ability of the drug to be effective in the above conditions, but warn against individuals experimenting with this drug. [13]

In addition, a study performed in Drosophila demonstrates that clioquinol can slow the pathogenesis of tauopathy model by removing the excessive zinc in the cell. [14]

Continued use and manufacture around the world

CountryComments
United StatesIn August 2004, Prana Biotechnology, an Australian company and P.N Gerolymatos S.A (PNG) agreed to recognize each other's rights to market clioquinol in their respective territories, with PNG holding right for European territories, and Prana holding rights for US and Japan.
CanadaIn 2001, the Canadian company Paladin Labs bought the rights to market Vioform from Novartis. Vioform is licensed for use in Canada as a topical anti-fungal.
Netherlands2004 and 2005 reports describe use in treatment of Dientamoeba fragilis and Entamoeba histolytica infection. [4]
IndiaManufactured by Eskay Iodine Pvt. Ltd., Vishal Laboratories, DNS Fine Chemicals [15] and LASA Laboratory [16]
ColombiaManufactured by "Altea Farmacéutica C.A." for "Scandinavia Pharma" [17]

See also

Related Research Articles

<span class="mw-page-title-main">Disulfiram</span> Chemical compound

Disulfiram is a medication used to support the treatment of chronic alcoholism by producing an acute sensitivity to ethanol. Disulfiram works by inhibiting the enzyme aldehyde dehydrogenase, causing many of the effects of a hangover to be felt immediately following alcohol consumption. Disulfiram plus alcohol, even small amounts, produces flushing, throbbing in the head and neck, a throbbing headache, respiratory difficulty, nausea, copious vomiting, sweating, thirst, chest pain, palpitation, dyspnea, hyperventilation, fast heart rate, low blood pressure, fainting, marked uneasiness, weakness, vertigo, blurred vision, and confusion. In severe reactions there may be respiratory depression, cardiovascular collapse, abnormal heart rhythms, heart attack, acute congestive heart failure, unconsciousness, convulsions, and death.

<i>Entamoeba histolytica</i> Anaerobic parasitic protist

Entamoeba histolytica is an anaerobic parasitic amoebozoan, part of the genus Entamoeba. Predominantly infecting humans and other primates causing amoebiasis, E. histolytica is estimated to infect about 35-50 million people worldwide. E. histolytica infection is estimated to kill more than 55,000 people each year. Previously, it was thought that 10% of the world population was infected, but these figures predate the recognition that at least 90% of these infections were due to a second species, E. dispar. Mammals such as dogs and cats can become infected transiently, but are not thought to contribute significantly to transmission.

<i>Entamoeba coli</i> Species of parasitic amoeba

Entamoeba coli is a non-pathogenic species of Entamoeba that frequently exists as a commensal parasite in the human gastrointestinal tract. E. coli is important in medicine because it can be confused during microscopic examination of stained stool specimens with the pathogenic Entamoeba histolytica. This amoeba does not move much by the use of its pseudopod, and creates a "sur place (non-progressive) movement" inside the large intestine. Usually, the amoeba is immobile, and keeps its round shape. This amoeba, in its trophozoite stage, is only visible in fresh, unfixed stool specimens. Sometimes the Entamoeba coli have parasites as well. One is the fungus Sphaerita spp. This fungus lives in the cytoplasm of the E. coli. While this differentiation is typically done by visual examination of the parasitic cysts via light microscopy, new methods using molecular biology techniques have been developed. The scientific name of the amoeba, E. coli, is often mistaken for the bacterium, Escherichia coli. Unlike the bacterium, the amoeba is mostly harmless, and does not cause as many intestinal problems as some strains of the E. coli bacterium. To make the naming of these organisms less confusing, "alternate contractions" are used to name the species for the purpose making the naming easier; for example, using Esch. coli and Ent. coli for the bacterium and amoeba, instead of using E. coli for both.

<span class="mw-page-title-main">Ionophore</span> Chemical entity that reversibly binds ions

In chemistry, an ionophore is a chemical species that reversibly binds ions. Many ionophores are lipid-soluble entities that transport ions across the cell membrane. Ionophores catalyze ion transport across hydrophobic membranes, such as liquid polymeric membranes or lipid bilayers found in the living cells or synthetic vesicles (liposomes). Structurally, an ionophore contains a hydrophilic center and a hydrophobic portion that interacts with the membrane.

<span class="mw-page-title-main">Leflunomide</span> Chemical compound

Leflunomide, sold under the brand name Arava among others, is an immunosuppressive disease-modifying antirheumatic drug (DMARD), used in active moderate-to-severe rheumatoid arthritis and psoriatic arthritis. It is a pyrimidine synthesis inhibitor that works by inhibiting dihydroorotate dehydrogenase.

<span class="mw-page-title-main">Auranofin</span> Chemical compound

Auranofin is a gold salt classified by the World Health Organization as an antirheumatic agent. It has the brand name Ridaura.

Antiprotozoal agents is a class of pharmaceuticals used in treatment of protozoan infection.

Subacute myelo-optic neuropathy (SMON) is an iatrogenic disease of the nervous system leading to a disabling paralysis, blindness and even death. Its defining manifestation was as an epidemic in Japan during the 1960s: the Japanese government estimated 11,000 were affected; however, the College of Medicine at the University of Tokyo put the number at 30,000, citing a lack of preservation of medical records for longer than five years and a lack of cooperation from doctors as the reasons for the discrepancy. On August 3, 1978, the Tokyo District Court ruled that the cause of SMON is Clioquinol. Its manufacturer, Ciba-Geigy, has publicly stated that "Medical products manufactured and sold by us have been responsible for the occurrence of [SMON] in Japan, we extend our apologies."

<span class="mw-page-title-main">Nitazoxanide</span> Broad-spectrum antiparasitic and antiviral medication

Nitazoxanide, sold under the brand name Alinia among others, is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections. It is indicated for the treatment of infection by Cryptosporidium parvum and Giardia lamblia in immunocompetent individuals and has been repurposed for the treatment of influenza. Nitazoxanide has also been shown to have in vitro antiparasitic activity and clinical treatment efficacy for infections caused by other protozoa and helminths; evidence as of 2014 suggested that it possesses efficacy in treating a number of viral infections as well.

<span class="mw-page-title-main">Diiodohydroxyquinoline</span> Chemical compound

The quinoline derivative diiodohydroxyquinoline (INN), or iodoquinol (USAN), brand name Diodoquin, can be used in the treatment of amoebiasis.

<span class="mw-page-title-main">Nitroxoline</span> Antibiotic chemical compound

Nitroxoline is an antibiotic that has been in use in Europe for about fifty years, and has proven to be very effective at combating biofilm infections. Nitroxoline was shown to cause a decrease in the biofilm density of P. aeruginosa infections, which would allow access to the infection by the immune system in vivo. It was shown that nitroxoline functions by chelating Fe2+ and Zn2+ ions from the biofilm matrix; when Fe2+ and Zn2+ were reintroduced into the system, biofilm formation was reconstituted. The activity of biofilm degradation is comparable to EDTA, but has a history of human use in clinical settings and therefore has a precedent with which to allow its use against “slimy” biofilm infections.

<span class="mw-page-title-main">Blastocystosis</span> Medical condition

Blastocystosis refers to a medical condition caused by infection with Blastocystis. Blastocystis is a protozoal, single-celled parasite that inhabits the gastrointestinal tracts of humans and other animals. Many different types of Blastocystis exist, and they can infect humans, farm animals, birds, rodents, amphibians, reptiles, fish, and even cockroaches. Blastocystosis has been found to be a possible risk factor for development of irritable bowel syndrome.

<span class="mw-page-title-main">Amoebiasis</span> Human disease caused by amoeba protists

Amoebiasis, or amoebic dysentery, is an infection of the intestines caused by a parasitic amoeba Entamoeba histolytica. Amoebiasis can be present with no, mild, or severe symptoms. Symptoms may include lethargy, loss of weight, colonic ulcerations, abdominal pain, diarrhea, or bloody diarrhea. Complications can include inflammation and ulceration of the colon with tissue death or perforation, which may result in peritonitis. Anemia may develop due to prolonged gastric bleeding.

<span class="mw-page-title-main">Amoebic brain abscess</span> Medical condition

Amoebic brain abscess is an affliction caused by the anaerobic parasitic protist Entamoeba histolytica. It is extremely rare; the first case being reported in 1849. Brain abscesses resulting from Entamoeba histolytica are difficult to diagnose and very few case reports suggest complete recovery even after the administration of appropriate treatment regimen.

<span class="mw-page-title-main">Dehydroemetine</span> Chemical compound

Dehydroemetine is a synthetically produced antiprotozoal agent similar to emetine in its anti-amoebic properties and structure, but it produces fewer side effects. In the United States, it is manufactured by Roche.

<span class="mw-page-title-main">Difetarsone</span> Chemical compound

Difetarsone is an antiprotozoal agent. Various studies have shown it to be particularly effective against Trichuris trichiura, commonly known as the whipworm. Prior to the drugs use in the early 1970s, there were few effective treatments for this infection. It has also been used to treat Entamoeba histolytica infections.

<span class="mw-page-title-main">PBT2</span> Chemical compound

PBT2 is a safe-for-human-use Zinc ionophore and an experimental drug candidate. It is a second-generation 8-hydroxyquinoline analog intended to be a successor to clioquinol and a potential treatment of Alzheimer's disease and Huntington's disease.

<i>Dientamoeba fragilis</i> Parasite of humans, pigs and gorillas

Dientamoeba fragilis is a species of single-celled excavates found in the gastrointestinal tract of some humans, pigs and gorillas. It causes gastrointestinal upset in some people, but not in others. It is an important cause of travellers diarrhoea, chronic diarrhoea, fatigue and, in children, failure to thrive. Despite this, its role as a "commensal, pathobiont, or pathogen" is still debated. D. fragilis is one of the smaller parasites that are able to live in the human intestine. Dientamoeba fragilis cells are able to survive and move in fresh feces but are sensitive to aerobic environments. They dissociate when in contact or placed in saline, tap water or distilled water.

<span class="mw-page-title-main">Zinc and the common cold</span> Overview of the relationship between Zinc and the common cold

Zinc supplements are a group of dietary supplements that are commonly used for the treatment of the common cold. The use of zinc supplements at doses in excess of 75 mg/day within 24 hours of the onset of symptoms has been shown to reduce the duration of cold symptoms by about 1 day in adults. Adverse effects with zinc supplements by mouth include bad taste and nausea. The intranasal use of zinc-containing nasal sprays has been associated with the loss of the sense of smell; consequently, in June 2009, the United States Food and Drug Administration (USFDA) warned consumers to stop using intranasal zinc.

Entamoeba moshkovskii is part of the genus Entamoeba. It is found in areas with polluted water sources, and is prevalent in places such as Malaysia, India, and Bangladesh, but more recently has made its way to Turkey, Australia, and North America. This amoeba is said to rarely infect humans, but recently this has changed. It is in question as to whether it is pathogenic or not. Despite some sources stating this is a free living amoeba, various studies worldwide have shown it contains the ability to infect humans, with some cases of pathogenic potential being reported. Some of the symptoms that often occur are diarrhea, weight loss, bloody stool, and abdominal pain. The first known human infection also known as the "Laredo strain" of Entamoebic mushkovskii was in Laredo, Texas in 1991, although it was first described by a man named Tshalaia in 1941 in Moscow, Russia. It is known to affect people of all ages and genders.

References

  1. Rohde W, Mikelens P, Jackson J, Blackman J, Whitcher J, Levinson W (August 1976). "Hydroxyquinolines inhibit ribonucleic acid-dependent deoxyribonucleic acid polymerase and inactivate Rous sarcoma virus and herpes simplex virus". Antimicrobial Agents and Chemotherapy. 10 (2): 234–240. doi:10.1128/aac.10.2.234. PMC   429727 . PMID   185949.
  2. Gholz LM, Arons WL (May 1964). "Prophylaxis and Therapy of Amebiasis and Shigellosis with Iodochlorhydroxyquin". The American Journal of Tropical Medicine and Hygiene. 13 (3): 396–401. doi:10.4269/ajtmh.1964.13.396. PMID   14162901.
  3. Kager PA (January 2005). "[Outbreak of amoebiasis in a Dutch family; tropics unexpectedly nearby]". Nederlands Tijdschrift voor Geneeskunde (in Dutch). 149 (1): 51–2, author reply 52–3. PMID   15651505.
  4. 1 2 Bosman DK, Benninga MA, van de Berg P, Kooijman GC, van Gool T (March 2004). "[Dientamoeba fragilis: possibly an important cause of persistent abdominal pain in children]". Nederlands Tijdschrift voor Geneeskunde (in Dutch). 148 (12): 575–579. PMID   15074181.
  5. Masters DK, Hopkins AD (May 1979). "Therapeutic trial of four amoebicide regimes in rural Zaire". The Journal of Tropical Medicine and Hygiene. 82 (5): 99–101. PMID   226725.
  6. Wadia NH (1984). "SMON as seen from Bombay". Acta Neurologica Scandinavica. Supplementum. 100: 159–164. PMID   6091394.
  7. Meade TW (September 1975). "Subacute myelo-optic neuropathy and clioquinol. An epidemiological case-history for diagnosis". British Journal of Preventive & Social Medicine. 29 (3): 157–169. doi:10.1136/jech.29.3.157. PMC   478909 . PMID   127638.
  8. Takasu T (November 2003). "[SMON--a model of the iatrogenic disease]". Rinsho Shinkeigaku = Clinical Neurology (in Japanese). 43 (11): 866–869. PMID   15152488.
  9. Ito M, Nishibe Y, Inoue YK (June 1998). "Isolation of Inoue-Melnick virus from cerebrospinal fluid of patients with epidemic neuropathy in Cuba". Archives of Pathology & Laboratory Medicine. 122 (6): 520–522. PMID   9625419.
  10. Costello LC, Franklin RB (December 2016). "A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer". Archives of Biochemistry and Biophysics. 611 (1): 100–112. doi:10.1016/j.abb.2016.04.014. PMC   5083243 . PMID   27132038.
  11. Nguyen T, Hamby A, Massa SM (August 2005). "Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model". Proceedings of the National Academy of Sciences of the United States of America. 102 (33): 11840–11845. Bibcode:2005PNAS..10211840N. doi: 10.1073/pnas.0502177102 . PMC   1187967 . PMID   16087879.
  12. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, et al. (July 2008). "Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta". Neuron. 59 (1): 43–55. doi: 10.1016/j.neuron.2008.06.018 . PMID   18614028. S2CID   17263833.
  13. "News: Old gastrointestinal drug slows aging, McGill researchers say". Archived from the original on 2011-02-10. Retrieved 2017-08-25.
  14. Huang Y, Wu Z, Cao Y, Lang M, Lu B, Zhou B (August 2014). "Zinc binding directly regulates tau toxicity independent of tau hyperphosphorylation". Cell Reports. 8 (3): 831–842. doi:10.1016/j.celrep.2014.06.047. PMC   4306234 . PMID   25066125.
  15. "Manufacturers of Clioquinol". DNS Fine Chemicals. 2016-01-06. Retrieved 23 December 2017.
  16. Herlekar O. "Clioquinol manufacturers India". Lasa labs. Archived from the original on 29 June 2019. Retrieved 12 March 2013.
  17. "Dermosupril C 0,1% desonide + 3% clioquinol for topical use" (PDF). Medihealth laboratories. Retrieved 19 September 2016.